About this Journal Submit a Manuscript Table of Contents 
Journal of Aging Research
Volume 2012 (2012), Article ID 121390, 16 pages
doi:10.1155/2012/121390
Review Article

Aging-Shifted Prostaglandin Profile in Endothelium as a Factor in Cardiovascular Disorders

Hao Qian, Na Luo, and Yuling Chi

Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA

Received 28 March 2011; Revised 10 October 2011; Accepted 28 October 2011

Academic Editor: Paula Bickford

Copyright © 2012 Hao Qian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. http://www.who.int/mediacentre/factsheets/fs317/en/index.html.
  2. J. R. Docherty, “Cardiovascular responses in ageing: a review,” Pharmacological Reviews, vol. 42, no. 2, pp. 103–125, 1990. View at Scopus
  3. A. M. Zeiher, H. Drexler, B. Saurbier, and H. Just, “Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension,” Journal of Clinical Investigation, vol. 92, no. 2, pp. 652–662, 1993. View at Scopus
  4. R. P. Brandes, I. Fleming, and R. Busse, “Endothelial aging,” Cardiovascular Research, vol. 66, no. 2, pp. 286–294, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. E. G. Lakatta and D. Levy, “Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease,” Circulation, vol. 107, no. 1, pp. 139–146, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. P. M. Rothwell, A. J. Coull, L. E. Silver et al., “Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study),” Lancet, vol. 366, no. 9499, pp. 1773–1783, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. L. Jayakody, T. Kappagoda, M. P. Senaratne, and A. B. Thomson, “Impairment of endothelium-dependent relaxation: an early marker for atherosclerosis in the rabbit,” British Journal of Pharmacology, vol. 94, no. 2, pp. 335–346, 1988. View at Scopus
  8. H. L. Elliott, “Endothelial dysfunction in cardiovascular disease: risk factor, risk marker, or surrogate end point?” Journal of Cardiovascular Pharmacology, vol. 32, supplement 3, pp. S74–S77, 1998. View at Scopus
  9. R. Fathi, B. Haluska, N. Isbel, L. Short, and T. H. Marwick, “The relative importance of vascular structure and function in predicting cardiovascular events,” Journal of the American College of Cardiology, vol. 43, no. 4, pp. 616–623, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. G. B. Mancini, “Vascular structure versus function: is endothelial dysfunction of independent prognostic importance or not?” Journal of the American College of Cardiology, vol. 43, no. 4, pp. 624–628, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. M. D. Herrera, C. Mingorance, R. Rodríguez-Rodríguez, and M. Alvarez de Sotomayor, “Endothelial dysfunction and aging: an update,” Ageing Research Reviews, vol. 9, no. 2, pp. 142–152, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. R. F. Furchgott and J. V. Zawadzki, “The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine,” Nature, vol. 288, no. 5789, pp. 373–376, 1980. View at Scopus
  13. J. Davignon and P. Ganz, “Role of endothelial dysfunction in atherosclerosis,” Circulation, vol. 109, no. 23, pp. III27–III32, 2004. View at Scopus
  14. D. S. Celermajer, K. E. Sorensen, D. J. Spiegelhalter, D. Georgakopoulos, J. Robinson, and J. E. Deanfield, “Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women,” Journal of the American College of Cardiology, vol. 24, no. 2, pp. 471–476, 1994. View at Scopus
  15. S. Taddei, A. Virdis, P. Mattei et al., “Aging and endothelial function in normotensive subjects and patients with essential hypertension,” Circulation, vol. 91, no. 7, pp. 1981–1987, 1995. View at Scopus
  16. S. Taddei, A. Virdis, P. Mattei et al., “Hypertension causes premature aging of endothelial function in humans,” Hypertension, vol. 29, no. 3, pp. 736–743, 1997. View at Scopus
  17. K. Egashira, T. Inou, Y. Hirooka et al., “Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans,” Circulation, vol. 88, no. 1, pp. 77–81, 1993. View at Scopus
  18. C. F. Küng and T. F. Lüscher, “Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta,” Hypertension, vol. 25, no. 2, pp. 194–200, 1995. View at Scopus
  19. M. Gerhard, M. A. Roddy, S. J. Creager, and M. A. Creager, “Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans,” Hypertension, vol. 27, no. 4, pp. 849–853, 1996. View at Scopus
  20. I. Eskurza, K. D. Monahan, J. A. Robinson, and D. R. Seals, “Effect of acute and chronic ascorbic acid on flow-mediated dilatation with sedentary and physically active human ageing,” Journal of Physiology, vol. 556, no. 1, pp. 315–324, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. L. Rodríguez-Mañas, S. Vallejo, P. López-Dóriga et al., “Endothelial dysfunction in aged humans is related with oxidative stress and vascular inflammation,” Aging Cell, vol. 8, no. 3, pp. 226–238, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. I. Shimizu and N. Toda, “Alterations with age of the response to vasodilator agents in isolated mesenteric arteries of the beagle,” British Journal of Pharmacology, vol. 89, no. 4, pp. 769–778, 1986. View at Scopus
  23. H. Moritoki, E. Hosoki, and Y. Ishida, “Age-related decrease in endothelium-dependent dilator response to histamine in rat mesenteric artery,” European Journal of Pharmacology, vol. 126, no. 1-2, pp. 61–67, 1986. View at Scopus
  24. K. Hongo, T. Nakagomi, N. F. Kassell et al., “Effects of aging and hypertension on endothelium-dependent vascular relaxation in rat carotid artery,” Stroke, vol. 19, no. 7, pp. 892–897, 1988. View at Scopus
  25. M. R. Hynes and S. P. Duckles, “Effect of increasing age on the endothelium-mediated relaxation of rat blood vessels in vitro,” Journal of Pharmacology and Experimental Therapeutics, vol. 241, no. 2, pp. 387–392, 1987. View at Scopus
  26. T. Koga, Y. Takata, K. Kobayashi, S. Takishita, Y. Yamashita, and M. Fujishima, “Age and hypertension promote endothelium-dependent contractions to acetylcholine in the aorta of the rat,” Hypertension, vol. 14, no. 5, pp. 542–548, 1989. View at Scopus
  27. J. Atkinson, R. Tatchum-Talom, and C. Capdeville-Atkinson, “Reduction of endothelial function with age in the mesenteric arterial bed of the normotensive rat,” British Journal of Pharmacology, vol. 111, no. 4, pp. 1184–1188, 1994. View at Scopus
  28. M. Tominaga, K. Fujii, I. Abe, Y. Takata, K. Kobayashi, and M. Fujishima, “Hypertension and ageing impair acetylcholine-induced vasodilation in rats,” Journal of Hypertension, vol. 12, no. 3, pp. 259–268, 1994. View at Scopus
  29. K. G. Stewart, Y. Zhang, and S. T. Davidge, “Aging increases PGHS-2-dependent vasoconstriction in rat mesenteric arteries,” Hypertension, vol. 35, no. 6, pp. 1242–1247, 2000. View at Scopus
  30. M. Y. Abeywardena, L. T. Jablonskis, and R. J. Head, “Age- and hypertension-induced changes in abnormal contractions in rat aorta,” Journal of Cardiovascular Pharmacology, vol. 40, no. 6, pp. 930–937, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. J. M. Muller-Delp, S. A. Spier, M. W. Ramsey, and M. D. Delp, “Aging impairs endothelium-dependent vasodilation in rat skeletal muscle arterioles,” American Journal of Physiology, vol. 283, no. 4, pp. H1662–H1672, 2002. View at Scopus
  32. E. Gomez, C. Schwendemann, S. Roger et al., “Aging and prostacyclin responses in aorta and platelets from WKY and SHR rats,” American Journal of Physiology, vol. 295, no. 5, pp. H2198–H2211, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. M. È. Gendron, N. Thorin-Trescases, L. Villeneuve, and E. Thorin, “Aging associated with mild dyslipidemia reveals that COX-2 preserves dilation despite endothelial dysfunction,” American Journal of Physiology, vol. 292, no. 1, pp. H451–H458, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. M. È. Gendron and E. Thorin, “A change in the redox environment and thromboxane A2 production precede endothelial dysfunction in mice,” American Journal of Physiology, vol. 293, no. 4, pp. H2508–H2515, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. C. C. Haudenschild, M. F. Prescott, and A. V. Chobanian, “Aortic endothelial and subendothelial cells in experimental hypertension and aging,” Hypertension, vol. 3, no. 3, pp. 148–153, 1981. View at Scopus
  36. C. C. Haudenschild and A. V. Chobanian, “Blood pressure lowering diminishes age-related changes in the rat aortic intima,” Hypertension, vol. 6, no. 2, pp. I-62–I-68, 1984. View at Scopus
  37. E. E. Soltis, “Effect of age on blood pressure and membrane-dependent vascular responses in the rat,” Circulation Research, vol. 61, no. 6, pp. 889–897, 1987. View at Scopus
  38. T. Koga, Y. Takata, K. Kobayashi, S. Takishita, Y. Yamashita, and M. Fujishima, “Ageing suppresses endothelium-dependent relaxation and generates contraction mediated by the muscarinic receptors in vascular smooth muscle of normotensive Wistar-Kyoto and spontaneously hypertensive rats,” Journal of Hypertension, vol. 6, no. 4, pp. S243–S245, 1988. View at Scopus
  39. Y. Iwama, T. Kato, M. Muramatsu et al., “Correlation with blood pressure of the acetylcholine-induced endothelium- derived contracting factor in the rat aorta,” Hypertension, vol. 19, no. 4, pp. 326–332, 1992. View at Scopus
  40. A. U. Ferrari, A. Radaelli, and M. Centola, “Aging and the cardiovascular system,” Journal of Applied Physiology, vol. 95, no. 6, pp. 2591–2597, 2003. View at Scopus
  41. R. L. Matz and R. Andriantsitohaina, “Age-related endothelial dysfunction: potential implications for pharmacotherapy,” Drugs and Aging, vol. 20, no. 7, pp. 527–550, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. R. L. Matz, M. A. de Sotomayor, C. Schott, J. C. Stoclet, and R. Andriantsitohaina, “Vascular bed heterogeneity in age-related endothelial dysfunction with respect to NO and eicosanoids,” British Journal of Pharmacology, vol. 131, no. 2, pp. 303–311, 2000.
  43. M. Barton, F. Cosentino, R. P. Brandes, P. Moreau, S. Shaw, and T. F. Lüscher, “Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin,” Hypertension, vol. 30, no. 4, pp. 817–824, 1997.
  44. I. Fleming and R. Busse, “NO: the primary EDRF,” Journal of Molecular and Cellular Cardiology, vol. 31, no. 1, pp. 5–14, 1999. View at Publisher · View at Google Scholar · View at PubMed
  45. M. R. Tschudi, M. Barton, N. A. Bersinger et al., “Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery,” Journal of Clinical Investigation, vol. 98, no. 4, pp. 899–905, 1996.
  46. W. L. Smith, “Localization of enzymes responsible for prostaglandin formation,” in Handbook of Eicosanoids: Prostaglandins and Related Lipids, A. L. Wmlis, Ed., vol. IA, pp. 175–184, CRC Press, Boca Raton, Fla, USA, 1987.
  47. J. R. Weeks, “Prostaglandins,” Annual Review of Pharmacology, vol. 12, pp. 317–336, 1972.
  48. R. I. Clyman, F. Mauray, C. Roman, and A. M. Rudolph, “PGE2 is a more potent vasodilator of the lamb ductus arteriosus than is either PGI2 or 6 keto PGF(1α),” Prostaglandins, vol. 16, no. 2, pp. 259–264, 1978.
  49. N. Nakahata, “Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology,” Pharmacology and Therapeutics, vol. 118, no. 1, pp. 18–35, 2008. View at Publisher · View at Google Scholar · View at PubMed
  50. S. Moncada, R. Gryglewski, S. Bunting, and J. R. Vane, “An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation,” Nature, vol. 263, no. 5579, pp. 663–665, 1976.
  51. S. Moncada, A. G. Herman, E. A. Higgs, and J. R. Vane, “Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium,” Thrombosis Research, vol. 11, no. 3, pp. 323–344, 1977.
  52. S. P. Williams, G. W. Dorn 2nd, and R. M. Rapoport, “Prostaglandin I2 mediates contraction and relaxation of vascular smooth muscle,” American Journal of Physiology, vol. 267, no. 2, pp. H796–H803, 1994.
  53. R. M. Rapoport and S. P. Williams, “Role of prostaglandins in acetylcholine-induced contraction of aorta from spontaneously hypertensive and Wistar-Kyoto rats,” Hypertension, vol. 28, no. 1, pp. 64–75, 1996.
  54. P. Gluais, M. Lonchampt, J. D. Morrow, P. M. Vanhoutte, and M. Feletou, “Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin,” British Journal of Pharmacology, vol. 146, no. 6, pp. 834–845, 2005. View at Publisher · View at Google Scholar · View at PubMed
  55. S. Bunting, S. Gryglewski, S. Moncada, and J. R. Vane, “Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation,” Prostaglandins, vol. 12, no. 6, pp. 897–913, 1976.
  56. R. R. Gorman, F. A. Fitzpatrick, and O. V. Miller, “Reciprocal regulation of human platelet cAMP levels by thromboxane A2 and prostacyclin,” Advances in Cyclic Nucleotide Research, vol. 9, pp. 597–609, 1978.
  57. S. Moncada and J. R. Vane, “The role of prostacyclin in vascular tissue,” Desty's Federal Procedure, vol. 38, no. 1, pp. 66–71, 1979.
  58. H. Shimokawa, N. A. Flavahan, R. R. Lorenz, and P. M. Vanhoutte, “Prostacyclin releases endothelium-derived relaxing factor and potentiates its action in coronary arteries of the pig,” British Journal of Pharmacology, vol. 95, no. 4, pp. 1197–1203, 1988.
  59. D. Abran, D. R. Varma, and S. Chemtob, “Regulation of prostanoid vasomotor effects and receptors in choroidal vessels of newborn pigs,” American Journal of Physiology, vol. 272, no. 3, pp. R995–R1001, 1997.
  60. Z. S. Katusic, J. T. Shepherd, and P. M. Vanhoutte, “Endothelium-dependent contractions to calcium ionophore A23187, arachidonic acid and acetylcholine in canine basilar arteries,” Stroke, vol. 19, no. 4, pp. 476–479, 1988.
  61. H. Shirahase, H. Usui, K. Kurahashi, M. Fujiwara, and K. Fukui, “Endothelium-dependent contraction induced by nicotine in isolated canine basilar artery-possible involvement of a thromboxane A2 (TXA2) like substance,” Life Sciences, vol. 42, no. 4, pp. 437–445, 1988.
  62. S. Taddei and P. M. Vanhoutte, “Role of endothelium in endothelin-evoked contractions in the rat aorta,” Hypertension, vol. 21, no. 1, pp. 9–15, 1993.
  63. T. Ge, H. Hughes, D. C. Junquero, K. K. Wu, P. M. Vanhoutte, and C. M. Boulanger, “Endothelium-dependent contractions are associated with both augmented expression of prostaglandin H synthase-1 and hypersensitivity to prostaglandin H2 in the SHR aorta,” Circulation Research, vol. 76, no. 6, pp. 1003–1010, 1995.
  64. P. Gluais, J. Paysant, C. Badier-Commander, T. Verbeuren, P. M. Vanhoutte, and M. Félétou, “In SHR aorta, calcium ionophore A-23187 releases prostacyclin and thromboxane A2 as endothelium-derived contracting factors,” American Journal of Physiology, vol. 291, no. 5, pp. H2255–H2264, 2006. View at Publisher · View at Google Scholar · View at PubMed
  65. P. Gluais, P. M. Vanhoutte, and M. Félétou, “Mechanisms underlying ATP-induced endothelium-dependent contractions in the SHR aorta,” European Journal of Pharmacology, vol. 556, no. 1–3, pp. 107–114, 2007. View at Publisher · View at Google Scholar · View at PubMed
  66. A. Hirao, K. Kondo, N. Inui, K. Umemura, K. Ohashi, and H. Watanabe, “Cyclooxygenase-dependent vasoconstricting factor(s) in remodelled rat femoral arteries,” Cardiovascular Research, vol. 79, no. 1, pp. 161–168, 2008. View at Publisher · View at Google Scholar · View at PubMed
  67. J. Nakano, R. B. McCloy, and A. V. Prancan, “Circulatory and pulmonary airway responses to different mixtures of prostaglandins E2 and F2α in dogs,” European Journal of Pharmacology, vol. 24, no. 1, pp. 61–66, 1973.
  68. G. J. Dusting and J. R. Vane, “Some cardiovascular properties of prostacyclin (PGI2) which are not shared by PGE2,” Circulation Research, vol. 46, no. 6, pp. I183–I187, 1980.
  69. J. Carter, J. A. Reynoldson, and G. D. Thorburn, “The effects of certain vasodilating prostaglandins on the coronary and hindlimb vascular beds of the conscious sheep,” Comparative Biochemistry and Physiology, vol. 83, no. 2, pp. 401–406, 1986.
  70. U. Neisius, R. Olsson, R. Rukwied, G. Lischetzki, and M. Schmelz, “Prostaglandin E2 induces vasodilation and pruritus, but no protein extravasation in atopic dermatitis and controls,” Journal of the American Academy of Dermatology, vol. 47, no. 1, pp. 28–32, 2002. View at Publisher · View at Google Scholar
  71. S. J. Gray and S. Heptinstall, “The effects of PGE2 and CL 115,347, an antihypertensive PGE2 analogue, on human blood platelet behaviour and vascular contractility,” European Journal of Pharmacology, vol. 114, no. 2, pp. 129–137, 1985.
  72. U. Förstermann, A. Mügge, U. Alheid, S. M. Bode, and J. C. Frölich, “Endothelium-derived relaxing factor (EDRF): a defence mechanism against platelet aggregation and vasospasm in human coronary arteries,” European Heart Journal, vol. 10, supplement F, pp. 36–43, 1989.
  73. J. E. Fabre, M. Nguyen, K. Athirakul et al., “Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation,” Journal of Clinical Investigation, vol. 107, no. 5, pp. 603–610, 2001.
  74. W. L. Smith, “Prostaglandin biosynthesis and its compartmentation in vascular smooth muscle and endothelial cells,” Annual Review of Physiology, vol. 48, pp. 251–262, 1986.
  75. X. Norel, “Prostanoid receptors in the human vascular wall,” The Scientific World Journal, vol. 7, pp. 1359–1374, 2007. View at Publisher · View at Google Scholar · View at PubMed
  76. N. Singh, S. Prasad, D. R. Singer, and R. J. MacAllister, “Ageing is associated with impairment of nitric oxide and prostanoid dilator pathways in the human forearm,” Clinical Science, vol. 102, no. 5, pp. 595–600, 2002. View at Publisher · View at Google Scholar
  77. M. Wang, A. M. Zukas, Y. Hui, E. Ricciotti, E. Puré, and G. A. FitzGerald, “Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 39, pp. 14507–14512, 2006. View at Publisher · View at Google Scholar · View at PubMed
  78. D. L. DeWitt, J. S. Day, W. K. Sonneburg, and W. L. Smith, “Concentrations of prostaglandin endoperoxide synthase and prostaglandin I2 synthase in the endothelium and smooth muscle of bovine aorta,” Journal of Clinical Investigation, vol. 72, no. 6, pp. 1882–1888, 1983.
  79. R. Doroudi, L. M. Gan, L. Selin Sjögren, and S. Jern, “Effects of shear stress on eicosanoid gene expression and metabolite production in vascular endothelium as studied in a novel biomechanical perfusion model,” Biochemical and Biophysical Research Communications, vol. 269, no. 1, pp. 257–264, 2000. View at Publisher · View at Google Scholar · View at PubMed
  80. C. D. Funk and G. A. FitzGerald, “COX-2 inhibitors and cardiovascular risk,” Journal of Cardiovascular Pharmacology, vol. 50, no. 5, pp. 470–479, 2007. View at Publisher · View at Google Scholar · View at PubMed
  81. J. N. Topper, J. Cai, D. Falb, and M. A. Gimbrone Jr., “Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 19, pp. 10417–10422, 1996.
  82. M. Onodera, I. Morita, Y. Mano, and S. Murota, “Differential effects of nitric oxide on the activity of prostaglandin endoperoxide H synthase-1 and -2 in vascular endothelial cells,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 62, no. 3, pp. 161–167, 2000. View at Publisher · View at Google Scholar
  83. D. W. Kawka, M. Ouellet, P. O. Hétu, I. I. Singer, and D. Riendeau, “Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium,” Biochimica et Biophysica Acta, vol. 1771, no. 1, pp. 45–54, 2007. View at Publisher · View at Google Scholar · View at PubMed
  84. E. H. Tang and P. M. Vanhoutte, “Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension,” Physiological Genomics, vol. 32, no. 3, pp. 409–418, 2008. View at Publisher · View at Google Scholar · View at PubMed
  85. Y. Numaguchi, M. Harada, H. Osanai et al., “Altered gene expression of prostacyclin synthase and prostacyclin receptor in the thoracic aorta of spontaneously hypertensive rats,” Cardiovascular Research, vol. 41, no. 3, pp. 682–688, 1999. View at Publisher · View at Google Scholar
  86. K. B. Kang, M. A. Rajanayagam, A. van der Zypp, and H. Majewski, “A role for cyclooxygenase in aging-related changes of β-adrenoceptor- mediated relaxation in rat aortas,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 375, no. 4, pp. 273–281, 2007. View at Publisher · View at Google Scholar · View at PubMed
  87. D. A. Graham and J. W. Rush, “Cyclooxygenase and thromboxane/prostaglandin receptor contribute to aortic endothelium-dependent dysfunction in aging female spontaneously hypertensive rats,” Journal of Applied Physiology, vol. 107, no. 4, pp. 1059–1067, 2009. View at Publisher · View at Google Scholar · View at PubMed
  88. W. T. Wong, X. Y. Tian, F. P. Leung et al., “Bone morphogenic protein-4 impairs endothelial function through oxidative stress-dependent cyclooxygenase-2 upregulation: implications on hypertension,” Circulation Research, vol. 107, no. 8, pp. 984–991, 2010. View at Publisher · View at Google Scholar · View at PubMed
  89. C. Qu, S. W. Leung, P. M. Vanhoutte, and R. Y. Man, “Chronic inhibition of nitric-oxide synthase potentiates endothelium-dependent contractions in the rat aorta by augmenting the expression of cyclooxygenase-2,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 2, pp. 373–380, 2010. View at Publisher · View at Google Scholar · View at PubMed
  90. T. Kato, Y. Iwama, K. Okumura, H. Hashimoto, T. Ito, and T. Satake, “Prostaglandin H2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat,” Hypertension, vol. 15, no. 5, pp. 475–481, 1990.
  91. P. J. Pagano, L. Lin, W. C. Sessa, and A. Nasjletti, “Arachidonic acid elicits endothelium-dependent release from the rabbit aorta of a constrictor prostanoid resembling prostaglandin endoperoxides,” Circulation Research, vol. 69, no. 2, pp. 396–405, 1991.
  92. F. X. Dai, J. Skopec, A. Diederich, and D. Diederich, “Prostaglandin H2 and thromboxane A2 are contractile factors in intrarenal arteries of spontaneously hypertensive rats,” Hypertension, vol. 19, no. 6, pp. 795–798, 1992.
  93. K. Shimizu, M. Muramatsu, Y. Kakegawa et al., “Role of prostaglandin H2 as an endothelium-derived contracting factor in diabetic state,” Diabetes, vol. 42, no. 9, pp. 1246–1252, 1993.
  94. K. C. Kent, L. J. Collins, F. T. Schwerin, M. K. Raychowdhury, and J. A. Ware, “Identification of functional PGH2/TxA2 receptors on human endothelial cells,” Circulation Research, vol. 72, no. 5, pp. 958–965, 1993.
  95. H. Asano, K. Shimizu, M. Muramatsu et al., “Prostaglandin H2 as an endothelium-derived contracting factor modulates endothelin-1-induced contraction,” Journal of Hypertension, vol. 12, no. 4, pp. 383–390, 1994.
  96. L. Lin, M. Balazy, P. J. Pagano, and A. Nasjletti, “Expression of prostaglandin H2-mediated mechanism of vascular contraction in hypertensive rats: relation to lipoxygenase and prostacyclin synthase activities,” Circulation Research, vol. 74, no. 2, pp. 197–205, 1994.
  97. M. Félétou, T. J. Verbeuren, and P. M. Vanhoutte, “Endothelium-dependent contractions in SHR: a tale of prostanoid TP and IP receptors,” British Journal of Pharmacology, vol. 156, no. 4, pp. 563–574, 2009. View at Publisher · View at Google Scholar · View at PubMed
  98. M. Hamberg and B. Samuelsson, “Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 71, no. 9, pp. 3400–3404, 1974.
  99. M. Hamberg, J. Svensson, T. Wakabayashi, and B. Samuelsson, “Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 71, no. 2, pp. 345–349, 1974.
  100. S. Moncada, P. Needleman, S. Bunting, and J. R. Vane, “Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition,” Prostaglandins, vol. 12, no. 3, pp. 323–335, 1976.
  101. P. Needleman, S. Moncada, S. Bunting, J. R. Vane, M. Hamberg, and B. Samuelsson, “Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides,” Nature, vol. 261, no. 5561, pp. 558–560, 1976. View at Publisher · View at Google Scholar
  102. N. A. Flavahan, “Balancing prostanoid activity in the human vascular system,” Trends in Pharmacological Sciences, vol. 28, no. 3, pp. 106–110, 2007. View at Publisher · View at Google Scholar · View at PubMed
  103. B. F. Mcadam, F. Catella-Lawson, I. A. Mardini, S. Kapoor, J. A. Lawson, and G. A. Fitzgerald, “Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 1, pp. 272–277, 1999. View at Publisher · View at Google Scholar
  104. G. E. Rovati, A. Sala, V. Capra, S. E. Dahlén, and G. Folco, “Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk,” Trends in Pharmacological Sciences, vol. 31, no. 3, pp. 102–107, 2010. View at Publisher · View at Google Scholar · View at PubMed
  105. K. K. Wu and J. Y. Liou, “Cellular and molecular biology of prostacyclin synthase,” Biochemical and Biophysical Research Communications, vol. 338, no. 1, pp. 45–52, 2005. View at Publisher · View at Google Scholar · View at PubMed
  106. J. Y. Liou, S. K. Shyue, M. J. Tsai, C. L. Chung, K. Y. Chu, and K. K. Wu, “Colocalization of prostacyclin synthase with prostaglandin H synthase-1 (PGHS-1) but not phorbol ester-induced PGHS-2 in cultured endothelial cells,” Journal of Biological Chemistry, vol. 275, no. 20, pp. 15314–15320, 2000. View at Publisher · View at Google Scholar
  107. R. Brandt, A. Dembinska-Kiec, R. J. Gryglewski, and J. Nowak, “Release of prostacyclin from the human pulmonary vascular bed in response to cholinergic stimulation,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 325, no. 1, pp. 69–75, 1984.
  108. X. Norel, I. Haye-Legrand, C. Labat, J. Benveniste, and C. Brink, “Antigen-induced contraction of human isolated lung preparations passively sensitized with monoclonal IgE: effects of indomethacin,” International Archives of Allergy and Applied Immunology, vol. 96, no. 4, pp. 368–375, 1991.
  109. C. J. Buzzard, S. L. Pfister, and W. B. Campbell, “Endothelium-dependent contractions in rabbit pulmonary artery are mediated by thromboxane A2,” Circulation Research, vol. 72, no. 5, pp. 1023–1034, 1993.
  110. C. Heymes, A. Habib, D. Yang et al., “Cyclo-oxygenase-1 and -2 contribution to endothelial dysfunction in ageing,” British Journal of Pharmacology, vol. 131, no. 4, pp. 804–810, 2000.
  111. R. A. Coleman, W. L. Smith, and S. Narumiya, “VIII. International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes,” Pharmacological Reviews, vol. 46, no. 2, pp. 205–229, 1994.
  112. P. Kääpä, L. Viinikka, and O. Ylikorkala, “Plasma prostacyclin from birth to adolescence,” Archives of Disease in Childhood, vol. 57, no. 6, pp. 459–461, 1982.
  113. J. M. Armstrong, N. Lattimer, S. Moncada, and J. R. Vane, “Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin F1α with those of prostaglandin E2 in rats and rabbits,” British Journal of Pharmacology, vol. 62, no. 1, pp. 125–130, 1978.
  114. Y. Cheng, M. Wang, Y. Yu, J. Lawson, C. D. Funk, and G. A. FitzGerald, “Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function,” Journal of Clinical Investigation, vol. 116, no. 5, pp. 1391–1399, 2006. View at Publisher · View at Google Scholar · View at PubMed
  115. S. Fischer, C. Bernutz, H. Meier, and P. C. Weber, “Formation of prostacyclin and thromboxane in man as measured by the main urinary metabolites,” Biochimica et Biophysica Acta, vol. 876, no. 2, pp. 194–199, 1986.
  116. I. Adatia, S. E. Barrow, P. D. Stratton, V. M. Miall-Allen, J. M. Ritter, and S. G. Haworth, “Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease,” Circulation, vol. 88, no. 5 I, pp. 2117–2122, 1993.
  117. O. Tokunaga, T. Yamada, J. I. Fan, and T. Watanabe, “Age-related decline in prostacyclin synthesis by human aortic endothelial cells: qualitative and quantitative analysis,” American Journal of Pathology, vol. 138, no. 4, pp. 941–949, 1991.
  118. K. Neubert, A. Haberland, I. Kruse, and I. Schimke, “The ratio of formation of prostacyclin/thromboxane A2 in HUVEC decreased in each subsequent passage,” Prostaglandins, vol. 54, no. 1, pp. 447–462, 1997. View at Publisher · View at Google Scholar
  119. S. H. Ferreira and J. R. Vane, “Prostaglandins: their disappearance from and release into the circulation,” Nature, vol. 216, no. 5118, pp. 868–873, 1967. View at Publisher · View at Google Scholar
  120. A. Ishihata, T. Ogaki, T. Aita, and Y. Katano, “Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats,” European Journal of Pharmacology, vol. 523, no. 1–3, pp. 119–126, 2005. View at Publisher · View at Google Scholar · View at PubMed
  121. W. T. Nicholson, B. Vaa, C. Hesse, J. H. Eisenach, and M. J. Joyner, “Aging Is Associated with reduced prostacyclin-mediated dilation in the human forearm,” Hypertension, vol. 53, no. 6, pp. 973–978, 2009. View at Publisher · View at Google Scholar · View at PubMed
  122. S. Hara, D. Kamei, Y. Sasaki, A. Tanemoto, Y. Nakatani, and M. Murakami, “Prostaglandin E synthases: understanding their pathophysiological roles through mouse genetic models,” Biochimie, vol. 92, no. 6, pp. 651–659, 2010. View at Publisher · View at Google Scholar · View at PubMed
  123. B. Samuelsson, R. Morgenstern, and P. J. Jakobsson, “Membrane prostaglandin E synthase-1: a novel therapeutic target,” Pharmacological Reviews, vol. 59, no. 3, pp. 207–224, 2007. View at Publisher · View at Google Scholar · View at PubMed
  124. A. V. Sampey, S. Monrad, and L. J. Crofford, “Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2,” Arthritis Research and Therapy, vol. 7, no. 3, pp. 114–117, 2005. View at Publisher · View at Google Scholar · View at PubMed
  125. M. Camacho, J. López-Belmonte, and L. Vila, “Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity,” Circulation Research, vol. 83, no. 4, pp. 353–365, 1998.
  126. T. Yang, “Microsomal prostaglandin e synthase-1 and blood pressure regulation,” Kidney International, vol. 72, no. 3, pp. 274–278, 2007. View at Publisher · View at Google Scholar · View at PubMed
  127. M. Wang, A. M. Zukas, Y. Hui, E. Ricciotti, E. Puré, and G. A. FitzGerald, “Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 39, pp. 14507–14512, 2006. View at Publisher · View at Google Scholar · View at PubMed
  128. Y. Sugimoto and S. Narumiya, “Prostaglandin E receptors,” Journal of Biological Chemistry, vol. 282, no. 16, pp. 11613–11617, 2007. View at Publisher · View at Google Scholar · View at PubMed
  129. A. Alfranca, M. A. Iñiguez, M. Fresno, and J. M. Redondo, “Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases,” Cardiovascular Research, vol. 70, no. 3, pp. 446–456, 2006. View at Publisher · View at Google Scholar · View at PubMed
  130. H. Shio, J. Shaw, and P. Ramwell, “Relation of cyclic AMP to the release and actions of prostaglandins,” Annals of the New York Academy of Sciences, vol. 185, pp. 327–335, 1971.
  131. E. W. Salzman, P. C. Kensler, and L. Levine, “Cyclic 3',5'-adenosine monophosphate in human blood platelets. IV. Regulatory role of cyclic amp in platelet function,” Annals of the New York Academy of Sciences, vol. 201, pp. 61–71, 1972.
  132. H. J. Weiss, A. L. Willis, D. Kuhn, and H. Brand, “Prostaglandin E2 potentiation of platelet aggregation induced by LASS endoperoxide: absent in storage pool disease, normal after aspirin ingestion,” British Journal of Haematology, vol. 32, no. 2, pp. 257–272, 1976.
  133. A. Morimoto, K. Morimoto, T. Watanabe, Y. Sakata, and N. Murakami, “Does an increase in prostaglandin E2 in the blood circulation contribute to a febrile response in rabbits?” Brain Research Bulletin, vol. 29, no. 2, pp. 189–192, 1992. View at Publisher · View at Google Scholar
  134. S. Bergstorem, R. Ryhage, B. Samuelsson, and J. Sjoevall, “Prostaglandins and related factors. 15. The structures of prostaglandin E1, F1-α, and F1-β,” The Journal of Biological Chemistry, vol. 238, pp. 3555–3564, 1963.
  135. M. J. Dunn, J. F. Liard, and F. Dray, “Basal and stimulated rates of renal secretion and excretion of prostaglandings E2, Falpha, and 13, 14-dihydro-15-keto Falpha in the dog,” Kidney International, vol. 13, no. 2, pp. 36–43, 1978.
  136. T. E. Liston and L. J. Roberts II, “Transformation of prostaglandin D2 to 9α,11β-(15S)-trihydroxyprosta-(5Z,13E)-dien-1-oic acid (9α,11β-prostaglandin F2): a unique biologically active prostaglandin produced enzymatically in vivo in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 18, pp. 6030–6034, 1985.
  137. C. R. Beasley, C. Robinson, and R. L. Featherstone, “9α,11β-prostaglandin F2, a novel metabolite of prostaglandin D2 is a potent contractile agonist of human and guinea pig airways,” Journal of Clinical Investigation, vol. 79, no. 3, pp. 978–983, 1987.
  138. R. J. Helliwell, L. F. Adams, and M. D. Mitchell, “Prostaglandin synthases: recent developments and a novel hypothesis,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 70, no. 2, pp. 101–113, 2004. View at Publisher · View at Google Scholar
  139. M. Fukunaga, N. Makita, L. J. Roberts 2nd, J. D. Morrow, K. Takahashi, and K. F. Badr, “Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells,” American Journal of Physiology, vol. 264, no. 6, pp. C1619–C1624, 1993.
  140. M. Abramovitz, Y. Boie, T. Nguyen et al., “Cloning and expression of a cDNA for the human prostanoid FP receptor,” Journal of Biological Chemistry, vol. 269, no. 4, pp. 2632–2636, 1994.
  141. S. Lake, H. Gullverg, J. Wahlqvist, et al., “Cloning of the rat and human prostaglandin F2 alpha receptors and the expression of the rat prostaglandin F2 alpha receptor,” FEBS Letters, vol. 355, no. 3, pp. 317–325, 1994.
  142. K. Sakamoto, T. Ezashi, K. Miwa et al., “Molecular cloning and expression of a cDNA of the bovine prostaglandin F2 alpha receptor,” Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 23, pp. 259–261, 1995.
  143. Y. Sugimoto, K. Hasumoto, T. Namba et al., “Cloning and expression of a cDNA for mouse prostaglandin F receptor,” Journal of Biological Chemistry, vol. 269, no. 2, pp. 1356–1360, 1994.
  144. J. Csepli and A. I. Csapo, “The effect of the prostaglandin F2α analogue ICI 81008 on uterine small arteries and on blood pressure,” Prostaglandins, vol. 10, no. 4, pp. 689–697, 1975.
  145. A. N. Hata and R. M. Breyer, “Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation,” Pharmacology and Therapeutics, vol. 103, no. 2, pp. 147–166, 2004. View at Publisher · View at Google Scholar · View at PubMed
  146. E. M. Smyth, T. Grosser, M. Wang, Y. Yu, and G. A. FitzGerald, “Prostanoids in health and disease,” Journal of Lipid Research, vol. 50, pp. S423–428, 2009. View at Publisher · View at Google Scholar · View at PubMed
  147. S. L. Wong, F. P. Leung, P. Vanhoutte, and Y. Huang, “Endothelium-dependent contractions in hamster aorta: the essential role of COX-2 and prostaglandin-2α,” Basic, Basic and Clinical Pharmacology and Toxicology, vol. 102, pp. 15–15, 2008.
  148. S. L. Wong, F. P. Leung, C. W. Lau et al., “Cyclooxygenase-2-derived prostaglandin F2α mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging,” Circulation Research, vol. 104, no. 2, pp. 228–235, 2009. View at Publisher · View at Google Scholar · View at PubMed
  149. Y. Yu, M. B. Lucitt, J. Stubbe et al., “Prostaglandin F2α elevates blood pressure and promotes atherosclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 19, pp. 7985–7990, 2009. View at Publisher · View at Google Scholar · View at PubMed
  150. J. W. Adams, D. S. Migita, M. K. Yu et al., “Prostaglandin F2α stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes,” Journal of Biological Chemistry, vol. 271, no. 2, pp. 1179–1186, 1996.
  151. J. Lai, H. Jin, R. Yang et al., “Prostaglandin F2α induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo,” American Journal of Physiology, vol. 271, no. 6, pp. H2197–H2208, 1996.
  152. K. Pönicke, C. Giessler, M. Grapow et al., “FP-receptor mediated trophic effects of prostanoids in rat ventricular cardiomyocytes,” British Journal of Pharmacology, vol. 129, no. 8, pp. 1723–1731, 2000.
  153. Y. Taba, T. Sasaguri, M. Miyagi et al., “Fluid shear stress induces lipocalin-type prostaglandin D2 synthase expression in vascular endothelial cells,” Circulation Research, vol. 86, no. 9, pp. 967–973, 2000.
  154. R. L. Jones, M. A. Giembycz, and D. F. Woodward, “Prostanoid receptor antagonists: development strategies and therapeutic applications,” British Journal of Pharmacology, vol. 158, no. 1, pp. 104–145, 2009. View at Publisher · View at Google Scholar · View at PubMed
  155. D. S. VanderEnde and J. D. Morrow, “Release of markedly increased quantities of prostaglandin D2 from the skin in vivo in humans after the application of cinnamic aldehyde,” Journal of the American Academy of Dermatology, vol. 45, no. 1, pp. 62–67, 2001. View at Publisher · View at Google Scholar · View at PubMed
  156. L. Walch, C. Labat, J. P. Gascard, V. de Montpreville, C. Brink, and X. Norel, “Prostanoid receptors involved in the relaxation of human pulmonary vessels,” British Journal of Pharmacology, vol. 126, no. 4, pp. 859–866, 1999.
  157. M. A. Wasserman, D. W. DuCharme, and R. L. Griffin, “Bronchopulmonary and cardiovascular effects of prostaglandin D2 in the dog,” Prostaglandins, vol. 13, no. 2, pp. 255–269, 1977.
  158. C. C. Hardy, C. Robinson, A. E. Tattersfield, and S. T. Holgate, “The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men,” New England Journal of Medicine, vol. 311, no. 4, pp. 209–213, 1984.
  159. S. L. Johnston, N. J. Freezer, W. Ritter, S. O'Toole, and P. H. Howarth, “Prostaglandin D2-induced bronchoconstriction is mediated only in part by the thromboxane prostanoid receptor,” European Respiratory Journal, vol. 8, no. 3, pp. 411–415, 1995.
  160. B. J. Whittle, S. Moncada, and J. R. Vane, “Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and O2 on platelet aggregation in different species,” Prostaglandins, vol. 16, no. 3, pp. 373–388, 1978.
  161. B. Cooper, “Diminished platelet adenylate cyclase activation by prostaglandin D2 in acute thrombosis,” Blood, vol. 54, no. 3, pp. 684–693, 1979.
  162. A. M. Siegl, “Receptors for PGI2 and PGD2 on human platelets,” Methods in Enzymology, vol. 86, pp. 179–192, 1982. View at Publisher · View at Google Scholar
  163. K. H. Thierauch, C. S. Stürzebecher, E. Schillinger et al., “Stable 9 beta- or 11 alpha-halogen-15-cyclohexyl-prostaglandins with high affinity to the PGD2-receptor,” Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 19, pp. 655–658, 1989.
  164. M. Kiriyama, F. Ushikubi, T. Kobayashi, M. Hirata, Y. Sugimoto, and S. Narumiya, “Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells,” British Journal of Pharmacology, vol. 122, no. 2, pp. 217–224, 1997. View at Publisher · View at Google Scholar · View at PubMed
  165. Y. Cheng, S. C. Austin, B. Rocca et al., “Role of prostacyclin in the cardiovascular response to thromboxane A2,” Science, vol. 296, no. 5567, pp. 539–541, 2002. View at Publisher · View at Google Scholar · View at PubMed
  166. T. Kobayashi, Y. Tahara, M. Matsumoto et al., “Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice,” Journal of Clinical Investigation, vol. 114, no. 6, pp. 784–794, 2004. View at Publisher · View at Google Scholar
  167. H. Francois, K. Athirakul, L. Mao, H. Rockman, and T. M. Coffman, “Role for thromboxane receptors in angiotensin-II-induced hypertension,” Hypertension, vol. 43, no. 2, pp. 364–369, 2004. View at Publisher · View at Google Scholar · View at PubMed
  168. A. I. Ally and D. F. Horrobin, “Thromboxane A2 in blood vessel walls and its physiological significance: relevance to thrombosis and hypertension,” Prostaglandins and Medicine, vol. 4, no. 6, pp. 431–438, 1980.
  169. G. W. Dorn and A. DeJesus, “Human platelet aggregation and shape change are coupled to separate thromboxane A2-prostaglandin H2 receptors,” American Journal of Physiology, vol. 260, no. 2, pp. H327–H334, 1991.
  170. R. F. Spurney, R. J. Bernstein, P. Ruiz, D. S. Pisetsky, and T. M. Coffman, “Physiologic role for enhanced renal thromboxane production in murine lupus nephritis,” Prostaglandins, vol. 42, no. 1, pp. 15–28, 1991. View at Publisher · View at Google Scholar
  171. S. D. Katugampola and A. P. Davenport, “Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT1 receptor antagonist losartan,” British Journal of Pharmacology, vol. 134, no. 7, pp. 1385–1392, 2001.
  172. W. Martin, “The combined role of atheroma, cholesterol, platelets, the endothelium and fibrin in heart attacks and strokes,” Medical Hypotheses, vol. 15, no. 3, pp. 305–322, 1984.
  173. G. W. Dorn, N. Liel, J. L. Trask, D. E. Mais, M. E. Assey, and P. V. Halushka, “Increased platelet thromboxane A2/prostaglandin H2 receptors in patients with acute myocardial infarction,” Circulation, vol. 81, no. 1, pp. 212–218, 1990.
  174. J. M. Dogne, J. Hanson, and D. Pratico, “Thromboxane, prostacyclin andisoprostanes: therapeutic targets in atherogenesis,” Trends in Pharmacological Sciences, vol. 26, no. 12, pp. 639–644, 2005.
  175. T. F. Lüscher, C. M. Boulanger, Y. Dohi, and Z. H. Yang, “Endothelium-derived contracting factors,” Hypertension, vol. 19, no. 2, pp. 117–130, 1992.
  176. M. Félétou and P. M. Vanhoutte, “Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture),” American Journal of Physiology, vol. 291, no. 3, pp. H985–H1002, 2006.
  177. D. J. Fitzgerald, L. Roy, F. Catella, and G. A. Fitzderald, “Platelet activation in unstable coronary disease,” New England Journal of Medicine, vol. 315, no. 16, pp. 983–989, 1986.
  178. K. Shinmura, K. Tamaki, T. Sato, H. Ishida, and R. Bolli, “Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor,” American Journal of Physiology, vol. 288, no. 5, pp. H2093–H2101, 2005. View at Publisher · View at Google Scholar · View at PubMed
  179. D. J. Fitzgerald, W. Rocki, R. Murray, G. Mayo, and G. A. FitzGerald, “Thromboxane A2 synthesis in pregnancy-induced hypertension,” Lancet, vol. 335, no. 8692, pp. 751–754, 1990. View at Publisher · View at Google Scholar
  180. J. C. Keith Jr., B. Spitz, and F. A. van Assche, “Thromboxane synthetase inhibition as a new therapy for preeclampsia: animal and human studies minireview,” Prostaglandins, vol. 45, no. 1, pp. 3–13, 1993. View at Publisher · View at Google Scholar
  181. G. Shams, L. J. Wallace, D. D. Miller, and D. R. Feller, “Effects of thromboxane A2 on thoracic aorta of young and old rats: use of selective thromboxane receptor antagonists,” Pharmacology, vol. 40, no. 1, pp. 27–32, 1990.
  182. P. M. Vanhoutte and E. H. Tang, “Endothelium-dependent contractions: when a good guy turns bad!,” Journal of Physiology, vol. 586, no. 22, pp. 5295–5304, 2008. View at Publisher · View at Google Scholar · View at PubMed
  183. A. Hornych, F. Forette, J. Bariety, C. Krief, J. Aumont, and M. Paris, “The influence of age on renal prostaglandin synthesis in man,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 43, no. 3, pp. 191–195, 1991. View at Publisher · View at Google Scholar
  184. J. Hou, K. Abe, and K. Yoshinaga, “The investigation about age-related changes in vasoactive substances of normal subjects and of patients with essential hypertension,” Nippon Jinzo Gakkai Shi, vol. 34, no. 3, pp. 287–293, 1992.
  185. T. F. Lüscher, “Imbalance of endothelium-derived relaxing and contracting factors: a new concept in hypertension?” American Journal of Hypertension, vol. 3, no. 4, pp. 317–330, 1990.
  186. B. W. Christman, C. D. McPherson, J. H. Newman et al., “An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension,” New England Journal of Medicine, vol. 327, no. 2, pp. 70–75, 1992.
  187. C. R. Woodman, E. M. Price, and M. H. Laughlin, “Selected Contribution: aging impairs nitric oxide and prostacyclin mediation of endothelium-dependent dilation in soleus feed arteries,” Journal of Applied Physiology, vol. 95, no. 5, pp. 2164–2170, 2003.
  188. M. H. Zou and V. Ullrich, “Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase,” FEBS Letters, vol. 382, no. 1-2, pp. 101–104, 1996. View at Publisher · View at Google Scholar
  189. F. Santilli, G. Davì, S. Basili et al., “Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment,” Journal of Thrombosis and Haemostasis, vol. 8, no. 5, pp. 914–922, 2010. View at Publisher · View at Google Scholar · View at PubMed
  190. M. M. Sellers and J. N. Stallone, “Sympathy for the devil: the role of thromboxane in the regulation of vascular tone and blood pressure,” American Journal of Physiology, vol. 294, no. 5, pp. H1978–H1986, 2008. View at Publisher · View at Google Scholar · View at PubMed
  191. M. Félétou, P. M. Vanhoutte, and T. J. Verbeuren, “The thromboxane/endoperoxide receptor (TP): the common villain,” Journal of Cardiovascular Pharmacology, vol. 55, no. 4, pp. 317–332, 2010. View at Publisher · View at Google Scholar
  192. C. Y. Xiao, A. Hara, K. Yuhki et al., “Roles of prostaglandin I2 and thromboxane A2 in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors,” Circulation, vol. 104, no. 18, pp. 2210–2215, 2001.
  193. Y. Cheng, S. C. Austin, B. Rocca et al., “Role of prostacyclin in the cardiovascular response to thromboxane A2,” Science, vol. 296, no. 5567, pp. 539–541, 2002. View at Publisher · View at Google Scholar · View at PubMed
  194. E. Arehart, J. Stitham, F. W. Asselbergs et al., “Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition,” Circulation Research, vol. 102, no. 8, pp. 986–993, 2008. View at Publisher · View at Google Scholar · View at PubMed
  195. R. Ross, “The pathogenesis of atherosclerosis: a perspective for the 1990s,” Nature, vol. 362, no. 6423, pp. 801–809, 1993. View at Publisher · View at Google Scholar · View at PubMed
  196. C. S. Baker, R. J. C. Hall, T. J. Evans et al., “Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 3, pp. 646–655, 1999.
  197. B. K. Hong, H. M. Kwon, B. K. Lee et al., “Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions,” Yonsei Medical Journal, vol. 41, no. 1, pp. 82–88, 2000.
  198. U. Schonbeck, G. K. Sukhova, P. Graber, S. Coulter, and P. Libby, “Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions,” American Journal of Pathology, vol. 155, no. 4, pp. 1281–1291, 1999.
  199. V. Stemme, J. Swedenborg, H. E. Claesson, and G. K. Hansson, “Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries,” European Journal of Vascular and Endovascular Surgery, vol. 20, no. 2, pp. 146–152, 2000. View at Publisher · View at Google Scholar · View at PubMed
  200. Y. F. Chen, S. Jowett, P. Barton et al., “Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation,” Health Technology Assessment, vol. 13, no. 49, pp. 1–320, 2009.
  201. C. S. Peter and C. Peter, “Prostaglandins, prostacyclin, and thromboxane in cardiovascular diseases,” Drug Development Research, vol. 7, no. 4, pp. 341–359, 1986.
  202. V. V. McLaughlin, S. P. Gaine, R. J. Barst et al., “Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension,” Journal of Cardiovascular Pharmacology, vol. 41, no. 2, pp. 293–299, 2003. View at Publisher · View at Google Scholar
  203. N. Toda, “Beraprost sodium,” Cardiovascular Drug Reviews, vol. 6, no. 3, pp. 222–238, 1988.
  204. T. Umetsu, T. Murata, Y. Tanaka, E. Osada, and S. Nishio, “Antithrombotic effect of TRK-100, a novel, stable PGI2 analogue,” Japanese Journal of Pharmacology, vol. 43, no. 1, pp. 81–90, 1987.
  205. T. Umetsu, T. Murata, and S. Nishio, “Studies on the antiplatelet effect of the stable epoprostenol analogue beraprost sodium and its mechanism of action in rats,” Arzneimittel-Forschung, vol. 39, no. 1, pp. 68–73, 1989.
  206. T. Murai, K. Muraoka, K. Saga et al., “Effect of beraprost sodium on peripheral circulation insufficiency in rats and rabbits,” Arzneimittel-Forschung, vol. 39, no. 8, pp. 856–859, 1989.
  207. X. L. Ma, G. Johnson 3rd, and A. M. Lefer, “Low doses of superoxide dismutase and a stable prostacyclin analogue protect in myocardial ischemia and reperfusion,” Journal of the American College of Cardiology, vol. 19, no. 1, pp. 197–204, 1992.
  208. P. S. Chan, P. Cervoni, P. A. Scully, M. A. Ronsberg, and R. C. Accomando, “Mechanism of action of a new prostaglandin antihypertensive, viprostol [CL 115 347; (dl)-15-deoxy-16-hydroxy-16(α/β)-vinyl-prostaglandin E2 methyl ester]: (I) Vasodilation,” Journal of Hypertension, vol. 4, no. 6, pp. 741–747, 1986.
  209. P. S. Chan, P. Cervoni, R. C. Accomando, G. J. Quirk, and M. A. Ronsgerg, “Mechanism of action of a new prostaglandin antihypertensive, viprostol [CL 115 347; (dl)-15-deoxy-16-hydroxy-16(α/β)-vinyl prostaglandin E2 methyl ester]: (II) Effects on the adrenergic nervous system,” Journal of Hypertension, vol. 4, no. 6, pp. 749–757, 1986.
  210. M. T. Olivari, T. B. Levine, and J. N. Cohn, “Evidence for a direct renal stimulating effect of prostaglandin E2 on renin release in patients with congestive heart failure,” Circulation, vol. 74, no. 6, pp. 1203–1207, 1986.
  211. J. A. Haas, T. G. Hammond, J. P. Granger, E. H. Blaine, and F. G. Knox, “Mechanism of natriuresis during intrarenal infusion of prostaglandins,” The American Journal of Physiology, vol. 247, no. 3, pp. F475–479, 1984.
  212. S. Katayama, A. A. Attallah, R. A. Stahl, D. L. Bloch, and J. B. Lee, “Mechanism of furosemide-induced natriuresis by direct stimulation of renal prostaglandin E2,” The American Journal of Physiology, vol. 247, no. 4, pp. F555–561, 1984.
  213. J. B. Stokes, “Integrated actions of renal medullary prostaglandins in the control of water excretion,” The American Journal of Physiology, vol. 240, no. 6, pp. F471–F480, 1981.
  214. P. M. Olley, F. Coceani, and E. Bodach, “E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations,” Circulation, vol. 53, no. 4, pp. 728–731, 1976.
  215. M. A. Heymann, “Pharmacologic use of prostaglandin E1 in infants with congenital heart disease,” American Heart Journal, vol. 101, no. 6, pp. 837–843, 1981.
  216. E. D. Silove, D. G. V. Roberts, and J. V. de Giovanni, “Evaluation of oral and low dose intravenous prostaglandin E2 in management of ductus dependent congenital heart disease,” Archives of Disease in Childhood, vol. 60, no. 11, pp. 1025–1030, 1985.
  217. E. D. Silove, J. Y. Coe, M. F. Shiu, et al., “Oral prostaglandin E2 in ductus-dependent pulmonary circulation,” Circulation, vol. 63, no. 3, pp. 682–688, 1981.
  218. G. I. Fiddler and P. Lumley, “Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review,” Circulation, vol. 81, supplement I, no. 1, pp. I -69–I -78, 1990.
  219. E. W. Jones, S. R. Cockbill, A. J. Cowley, et al., “Effects of dazoxiben and low-dose aspirin on platelet behaviour in man,” British Journal of Clinical Pharmacology, vol. 15, supplement 1, pp. 39S–44S, 1983.
  220. M. A. Villalobos, J. P. de La Cruz, R. Escalante, M. M. Arrebola, A. Guerrero, and F. Sánchez de la Cuesta, “Effects of camonagrel, a selective inhibitor of platelet thromboxane synthase, on the platelet-subendothelium interaction,” Pharmacology, vol. 69, no. 1, pp. 44–50, 2003. View at Publisher · View at Google Scholar · View at PubMed
  221. S. J. Coker and J. R. Parratt, “The effects of dazoxihen on arrhythmias and ventricular fibrillation induced by coronary, artery occlusion and reperfusion,” British Journal of Clinical Pharmacology, vol. 15, supplement 1, pp. 87S–95S, 1983.
  222. S. J. Coker, “Further evidence that thromboxane exacerbates arrhythmias: effects of UK38485 during coronary artery occlusion and reperfusion in anaesthetized greyhounds,” Journal of Molecular and Cellular Cardiology, vol. 16, no. 7, pp. 633–641, 1984.
  223. G. G. Neri Serneri, S. Coccheri, E. Marubini, and F. Violi, “Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study,” European Heart Journal, vol. 25, no. 20, pp. 1845–1852, 2004. View at Publisher · View at Google Scholar · View at PubMed
  224. A. Vetrano, M. Milani, and G. Corsini, “Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-intensity oral anticoagulation in patients with acute myocardial infarction: a controlled randomized pilot trial,” Giornale Italiano di Cardiologia Journal, vol. 29, no. 5, pp. 524–528, 1999.
  225. M. Cocozza, T. Picano, U. Oliviero, N. Russo, V. Coto, and M. Milani, “Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution: a two-year, double-blind, placebo-controlled study in diabetic patients,” Stroke, vol. 26, no. 4, pp. 597–601, 1995.
  226. M. G. Hennerici, M. L. Bots, I. Ford, S. Laurent, and P. J. Touboul, “Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) trial,” Cardiovascular Drugs and Therapy, vol. 24, no. 2, pp. 175–180, 2010. View at Publisher · View at Google Scholar · View at PubMed
  227. S. Simonet, J. J. Descombes, M. O. Vallez, et al., “S 18886, a new thromboxane (TP)-receptor antagonist is the active isomer of S 18204 in all species, except in the guinea-pig,” Advances in Experimental Medicine and Biology, vol. 433, pp. 173–176, 1997.
  228. A. G. Johnson, T. V. Nguyen, and R. O. Day, “Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis,” Annals of Internal Medicine, vol. 121, no. 4, pp. 289–300, 1994.
  229. S. K. Swan, D. W. Rudy, K. C. Lasseter et al., “Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial,” Annals of Internal Medicine, vol. 133, no. 1, pp. 1–9, 2000.
  230. C. J. Hawkey, G. M. Hawkey, S. Everitt, M. M. Skelly, W. A. Stack, and D. Gray, “Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs,” British Journal of Clinical Pharmacology, vol. 61, no. 6, pp. 730–737, 2006. View at Publisher · View at Google Scholar · View at PubMed
  231. S. Husain, N. P. Andrews, D. Mulcahy, J. A. Panza, and A. A. Quyyumi, “Aspirin improves endothelial dysfunction in atherosclerosis,” Circulation, vol. 97, no. 8, pp. 716–720, 1998.
  232. V. Fuster, M. L. Dyken, P. S. Vokonas, and C. Hennekens, “Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group,” Circulation, vol. 87, no. 2, pp. 659–675, 1993.
  233. Antiplatelet Trials Collaboration, “Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients,” British Medical Journal, vol. 308, no. 6921, pp. 81–106, 1994.
  234. G. J. Roth and P. W. Majerus, “The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein, Annual Review of Pharmacology and Toxicology,” The Journal of Clinical Investigation, vol. 56, no. 3, pp. 624–632, 1975.
  235. P. J. Loll, D. Picot, and R. M. Garavito, “The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase,” Nature Structural & Molecular Biology, vol. 2, no. 8, pp. 637–643, 1995.
  236. J. R. Vane, Y. S. Bakhle, and R. M. Botting, “Cyclooxygenases 1 and 2,” Annual Review of Pharmacology and Toxicology, vol. 38, pp. 97–120, 1998.
  237. P. Pignatelli, S. di Santo, F. Barillá, C. Gaudio, and F. Violi, “Multiple anti-atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance,” Journal of Thrombosis and Haemostasis, vol. 6, no. 10, pp. 1832–1834, 2008. View at Publisher · View at Google Scholar · View at PubMed
  238. J. Dawson, T. Quinn, M. Rafferty et al., “Aspirin resistance and compliance with therapy,” Cardiovascular Therapeutics, vol. 29, no. 5, pp. 301–307, 2011. View at Publisher · View at Google Scholar · View at PubMed
  239. G. Di Minno, “Aspirin resistance and platelet turnover: a 25-year old issue,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 21, no. 8, pp. 542–545, 2011. View at Publisher · View at Google Scholar · View at PubMed
  240. A. Szczeklik, J. Musiał, A. Undas, and M. Sanak, “Aspirin resistance,” Journal of Thrombosis and Haemostasis, vol. 3, no. 8, pp. 1655–1662, 2005. View at Publisher · View at Google Scholar · View at PubMed
  241. T. Goodman, A. Ferro, and P. Sharma, “Pharmacogenetics of aspirin resistance: a comprehensive systematic review,” British Journal of Clinical Pharmacology, vol. 66, no. 2, pp. 222–331, 2008. View at Publisher · View at Google Scholar · View at PubMed
  242. G. Krasopoulos, S. J. Brister, W. S. Beattie, and M. R. Buchanan, “Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis,” British Medical Journal, vol. 336, no. 7637, pp. 195–198, 2008. View at Publisher · View at Google Scholar · View at PubMed
  243. J. D. Snoep, M. M. Hovens, J. C. Eikenboom, J. G. van der Bom, and M. V. Huisman, “Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis,” Archives of Internal Medicine, vol. 167, no. 15, pp. 1593–1599, 2007. View at Publisher · View at Google Scholar · View at PubMed
  244. J. W. Eikelboom, J. Hirsh, J. I. Weitz, M. Johnston, Q. Yi, and S. Yusuf, “Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events,” Circulation, vol. 105, no. 14, pp. 1650–1655, 2002. View at Publisher · View at Google Scholar
  245. H. H. Tai, H. Cho, M. Tong, and Y. Ding, “NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological function,” Current Pharmaceutical Design, vol. 12, no. 8, pp. 955–962, 2006. View at Publisher · View at Google Scholar
  246. M. E. Rudock, Y. Liu, J. T. Ziegler et al., “Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the Diabetes Heart Study,” Atherosclerosis, vol. 203, no. 2, pp. 459–465, 2009. View at Publisher · View at Google Scholar · View at PubMed
  247. J. Helmersson, J. Ärnlöv, T. Axelsson, and S. Basu, “A polymorphism in the cyclooxygenase 1 gene is associated with decreased inflammatory prostaglandin F2α formation and lower risk of cardiovascular disease,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 80, no. 1, pp. 51–56, 2009. View at Publisher · View at Google Scholar · View at PubMed
  248. T. Nakayama, “Prostacyclin synthase gene: genetic polymorphisms and prevention of some cardiovascular diseases,” Current Medicinal Chemistry: Cardiovascular and Hematological Agents, vol. 3, no. 2, pp. 157–164, 2005. View at Publisher · View at Google Scholar
  249. J. Stitham, A. Stojanovic, and J. Hwa, “Impaired receptor binding and activation associated with a human prostacyclin receptor polymorphism,” Journal of Biological Chemistry, vol. 277, no. 18, pp. 15439–15444, 2002. View at Publisher · View at Google Scholar · View at PubMed
  250. R. N. Lemaitre, K. Rice, K. Marciante et al., “Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke,” Atherosclerosis, vol. 204, no. 2, pp. e58–e63, 2009. View at Publisher · View at Google Scholar · View at PubMed
  251. M. Hamberg and B. Samuelsson, “On the metabolism of prostaglandins E 1 and E 2 in man,” Journal of Biological Chemistry, vol. 246, no. 22, pp. 6713–6721, 1971.
  252. R. Nomura, R. Lu, M. L. Pucci, and V. L. Schuster, “The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase,” Molecular Pharmacology, vol. 65, no. 4, pp. 973–978, 2004. View at Publisher · View at Google Scholar · View at PubMed
  253. H. Y. Chang, J. Locker, R. Lu, and V. L. Schuster, “Failure of postnatal ductus arteriosus closure in prostaglandin transporter-deficient mice,” Circulation, vol. 121, no. 4, pp. 529–536, 2010. View at Publisher · View at Google Scholar · View at PubMed
  254. Y. Chi, J. Min, J. F. Jasmin, M. P. Lisanti, Y. T. Chang, and V. L. Schuster, “Development of a high affinity inhibitor of the prostaglandin transporter PGT,” Journal of Pharmacology and Experimental Therapeutics, vol. 339, no. 2, pp. 529–536, 2011. View at Publisher · View at Google Scholar · View at PubMed